' Unrelenting ' : 20-Year Recurrence Risks in Breast Cancer ' Unrelenting ' : 20-Year Recurrence Risks in Breast Cancer

Clinicians have new long-term data to use in discussions with patients with estrogen receptor-positive breast cancer who have been treated with 5 years of endocrine therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news